ORMPライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:44):

Stats
本日の出来高	29 457.00
平均出来高	169 406
時価総額	99.27M
EPS	$0 ( 2024-03-04 )
次の収益日	( $0.0200 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	17.50
ATR14	$0.0110 (0.45%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-17	Reznick Yehuda	Buy	29 800	Common Stock
2024-04-01	Reznick Yehuda	Buy	0
2024-01-30	Aghion Daniel	Buy	3 750	Common Stock
2024-01-04	Kidron Miriam	Buy	295 500	Common Stock
2024-01-04	Kidron Nadav	Buy	329 000	Common Stock

INSIDER POWER
92.93
Last 95 transactions
Buy: 3 987 636 \| Sell: 392 701

ボリューム相関

長: -0.09 (neutral)

短: -0.59 (weak negative)

Signal:(55.204) Neutral

Oramed Pharmaceuticals 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Oramed Pharmaceuticals 相関 - 通貨/商品

0.37
( neutral )

0.42
( neutral )

0.00
( neutral )

0.46
( neutral )

0.56
( weak )

-0.34
( neutral )

Oramed Pharmaceuticals 財務諸表

Annual	2022
収益:	$2.70M
総利益:	$2.70M (100.00 %)
EPS:	$-0.970

FY	2022
収益:	$2.70M
総利益:	$2.70M (100.00 %)
EPS:	$-0.970

FY	2021
収益:	$2.70M
総利益:	$0.00 (0.00 %)
EPS:	$-0.780

FY	2020
収益:	$2.71M
総利益:	$2.71M (100.00 %)
EPS:	$-0.560

Financial Reports:

No articles found.

Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.